Literature DB >> 22469741

Evaluation of surgical resection for pancreatic carcinoma at a Japanese single cancer institute.

Atsushi Nanashima1, Syuuichi Tobinaga, Takafumi Abo, Kazuhiko Hatano, Hiroaki Takeshita, Takashi Nonaka, Shigekazu Hidaka, Kenji Tanaka, Masaki Kunizaki, Terumitsu Sawai, Toru Yasutake, Takeshi Nagayasu.   

Abstract

BACKGROUND/AIMS: Surgical resection is a radical treatment option for pancreatic carcinoma (PC); however, it is still difficult to cure and patient prognosis is poor at this stage.
METHODOLOGY: We examined the demographics, surgical records and outcome in 64 patients with hilar PC undergoing surgical resection.
RESULTS: Pancreatoduodenectomy (PD) was carried out in 48 patients, distal pancreatectomy (DP) in 14 and total pancreatectomy in two. Postoperative complications were observed in 18 patients (28%) but no hospital deaths. All stage I patients showed carcinoma in situ of intraductal papillary mucinous carcinoma (IPMC). Postoperative adjuvant chemotherapy was performed in 15 patients (23%) using gemcitabine or S-1. Cancer recurrence was observed in 36 patients (56%) and 31 died of carcinoma. The 5-year cancer-free and overall survival rate was 12% and 14%, respectively. CA19-9 level, morphological type, T category, lymph node metastasis, extrapancreatic nerve plexus invasion, retropancreatic tissue invasion, distal bile duct invasion, duodenal invasion and arterial system invasion were significant poor prognostic factors; however, portal vein system invasion was not significantly associated with prognosis. Cancer infiltration at bile duct cut-end and dissected peripancreatic tissue margin and presence of residual tumor showed a poor prognosis. Surgical prognosis in only non-invasive IPMC was satisfactory.
CONCLUSIONS: Radically extended surgical resection is necessary and newly effective adjuvant chemotherapy is a promising modality to improve patient survival in PC patients.

Entities:  

Mesh:

Year:  2012        PMID: 22469741     DOI: 10.5754/hge10038

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  7 in total

Review 1.  Meta-analysis of quantitative diffusion-weighted MR imaging in differentiating benign and malignant pancreatic masses.

Authors:  Xiang-Ke Niu; Anup Bhetuwal; Sushant Das; Ying-Quan Xiao; Feng Sun; Li-Chuan Zeng; Han-Feng Yang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-12-06

2.  HLA-G impairs host immune response and predicts poor prognosis in pancreatic cancer.

Authors:  Li Zhou; Zhe-Yu Niu; Zhi-Yong Liang; Wei-Xun Zhou; Lei You; Meng-Yi Wang; Lu-Tian Yao; Quan Liao; Yu-Pei Zhao
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

3.  A Radiomics Nomogram for the Preoperative Prediction of Lymph Node Metastasis in Pancreatic Ductal Adenocarcinoma.

Authors:  Jiahao Gao; Fang Han; Yingying Jin; Xiaoshuang Wang; Jiawen Zhang
Journal:  Front Oncol       Date:  2020-08-27       Impact factor: 6.244

Review 4.  Pancreatic Cancer: 80 Years of Surgery-Percentage and Repetitions.

Authors:  Birgir Gudjonsson
Journal:  HPB Surg       Date:  2016-10-25

5.  Relationship Between Radiomics and Risk of Lymph Node Metastasis in Pancreatic Ductal Adenocarcinoma.

Authors:  Yun Bian; Shiwei Guo; Hui Jiang; Suizhi Gao; Chenwei Shao; Kai Cao; Xu Fang; Jing Li; Li Wang; Wenda Hua; Jianming Zheng; Gang Jin; Jianping Lu
Journal:  Pancreas       Date:  2019-10       Impact factor: 3.327

6.  Radiomics nomogram for the preoperative prediction of lymph node metastasis in pancreatic ductal adenocarcinoma.

Authors:  Yun Bian; Shiwei Guo; Hui Jiang; Suizhi Gao; Chengwei Shao; Kai Cao; Xu Fang; Jing Li; Li Wang; Chao Ma; Jianming Zheng; Gang Jin; Jianping Lu
Journal:  Cancer Imaging       Date:  2022-01-06       Impact factor: 3.909

7.  Risk factors of liver metastasis from advanced pancreatic adenocarcinoma: a large multicenter cohort study.

Authors:  Dong S; Wang L; Guo Y B; Ying H F; Shen X H; Meng Z Q; Chen Hao; Chen Q W; Li Z S
Journal:  World J Surg Oncol       Date:  2017-07-03       Impact factor: 2.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.